News | November 11, 2013

Women and African-Americans at Higher Risk of Heart Attack from Atrial Fibrillation than Men and Whites

cardiac diagnostics clinical trial s tudy atrial fibrillation therapies ep lab

November 11, 2013 — Doctors have known for years that atrial fibrillation (AF) increases the risk for stroke, but now researchers at Wake Forest Baptist Medical Center have shown that it also increases the risk for heart attack. In fact, for women and African Americans, it more than doubles the risk. The study is published in the Nov. 4 issue of JAMA Internal Medicine.
 
Approximately three million people in the United States have AF, a number that is expected to double in the next couple of decades, according to Elsayed Soliman, M.D., director, Epidemiological Cardiology Research Center (EPICARE), Wake Forest Baptist Medical Center and lead author of the study. Patients with AF have three to five times the risk of stroke and double the risk of mortality compared to those without AF.
 
“AF is a disease of aging and it is common, costly and has lots of complications,” Soliman said. “Our study showed that patients with AF, especially women and African-Americans, are at an increased risk of heart attack compared to those without AF.”
 
The prospective study included 23,928 participants without coronary heart disease from Reasons for Geographic and Racial Differences in Stroke (REGARDS), a large biracial population-based cohort study. The participants were enrolled between 2003 and 2007 and were followed through December 2009.
 
In the study, the overall increase in risk of heart attack in those with AF, compared to those without AF, was about 70 percent even after taking into account other cardiovascular disease risk factors such as hypertension, high cholesterol, body mass index and history of stroke and vascular disease. That risk was more than double in women and African Americans, but less than 50 percent for men and whites, Soliman said.
 
These findings add to the growing concerns of the seriousness of AF as a public health burden.
 
“Traditionally, blood thinners are used to manage AF complications such as stroke, but now there is another dimension to the problem. We need to determine the best strategy to prevent heart attack in AF patients while still dealing with potential stroke risk,” Soliman said. “In our study, individuals taking blood thinners were at lower risk for heart attack from AF, suggesting a potential role for blood thinners in prevention of heart attacks in AF patients.”
 
For more information: jama.jamanetwork.com

Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now